Sponsors keep buying tools to fix a problem that lives in the architecture — and the fix has to be installed before the protocol is written.
At the PanAgora Clinical Trial Innovation Summit this spring, a leading global sponsor did something most sponsors avoid in public: it put a number on its own ceiling. After eighteen months running one of the most disciplined innovation operating models in the industry, the company reported that site adoption of any given new tactic had reached seventy-nine percent — and named that figure, on stage, as the weak point in an otherwise mature system.
Seventy-nine percent is the signature of a problem the technology was never built to touch — and no amount of better software moves it.
Clinical development keeps spending against the wrong diagnosis: it treats a structural problem as a tooling problem, and pays for the mistake in billions spent on pilots that never scaled and years lost to rollouts that should have been predictable.
A decade of pilot enthusiasm has produced proof-of-concept successes and a portfolio of stalled rollouts. Sponsors test new technologies, celebrate early wins, and watch the effort dissolve under operational weight — a pattern so common it has a name, pilot purgatory, and a cost to match: roughly eighty percent of life-sciences AI projects never scale beyond the pilot. The most disciplined response the industry has produced — recently documented by Moe Alsumidaie in Clinical Trial Vanguard’s coverage of the PanAgora CTI Summit — comes from this sponsor, which has restructured clinical innovation around portfolio-level governance rather than trial-level pilots. It is also the most useful diagnostic of why even good operating models stall.
The model engages nine to twelve months before first-patient-in, defines strategy at the project level, and measures adoption, effectiveness, and impact — stopping tactics that fail to deliver. Eighteen months in, it supports more than thirty projects across sixty to a hundred studies. By any benchmark, this is mature governance. And yet proving out a single tactic still takes two to three years, and site adoption sits stubbornly at seventy-nine percent — a ceiling this sponsor publicly named as the weak point in its own model. A system this disciplined stalling this clearly is the tell: something structural sits beneath it, untouched by even the most sophisticated governance.
“Rather than finding a technology and searching for a trial to test it on,” a senior portfolio innovation leader at the sponsor told the summit, “the team now starts with the operational challenge.” The instinct is exactly right. By the sponsor’s own numbers, it is also not yet enough.
Sites Don’t Reject Innovation. They Reject Variability.
Walk into a research site and count the systems. Industry surveys put the number above twenty separate platforms in daily use, with most coordinators running three or more CTMS environments at once — a drag on trial conduct that researchers have begun to quantify formally. Every sponsor that shows up brings a new login, a new data model, a new definition of “done.” The tax is cognitive, it compounds with every protocol, and it has nothing to do with whether the latest tool is any good.
That reframes the seventy-nine percent. The figure tracks something other than how persuasive an innovation is — it measures how much structural variability a site is asked to absorb before the innovation even arrives.
Why Pilots Fail
Innovation enters too late, into a substrate that is at once locked and unstable. By the time a new tactic arrives, the scientific, operational, and data-flow decisions are already frozen, and the architecture required for scale was compromised before anyone wrote the pilot charter. Innovation becomes decorative — a layer bolted onto a protocol never designed to support it. Each rollout demands its own re-mapping, re-validation, and re-negotiation. Run that across sixty to a hundred studies and you have built, by hand, the two-to-three-year scaling cycle.
And the substrate keeps growing less stable, not more. Between 2010 and 2020, the data a single protocol collects roughly tripled while endpoints nearly doubled and investigative sites per trial rose sixty percent; the share of protocols carrying substantial amendments climbed from sixty-six to eighty-two percent. Each new layer is one more thing every future innovation must map itself onto — at T-zero, when nothing moves without a deviation.
The missing layer has a name: pre-protocol invariants — the stable, non-negotiable structural constraints that anchor data, workflow, and operational expectations across an entire portfolio, fixed before the first protocol is written. Lock them, and innovation finally has something solid to attach to. Skip them, and every attempt becomes a one-off integration problem solved from scratch.
The Five Invariants That Determine Whether Innovation Survives Scale
1. Semantic and data-lineage invariants. Definitions, transformations, and lineage must mean the same thing in every study across the portfolio. CDISC’s SDTM standardizes how data is tabulated for submission, but that is the end of the pipeline, not the start — it does not guarantee that two studies defined “response” the same way at capture. Without that consistency upstream, every new tool inherits a fresh re-mapping problem — the silent driver of the two-to-three-year cycle.
2. Workflow decision-point invariants. Operational logic must remain stable across studies. When decision boundaries — dose modification, discontinuation, escalation — drift from trial to trial, technology cannot integrate predictably, because the thing it integrates with keeps moving.
3. Site-facing operational invariants. Every new login, workflow, and data model adds cognitive load to a site already running more than twenty systems. Structural predictability — one identity layer, one support pathway, one interaction model — is the currency of site adoption, and its absence is the structural reason even best-in-class governance finds seventy-nine percent so hard to move.
4. Evidence-threshold invariants. Pilots fail because success gets defined after the results are in. Predefined criteria for adoption, continuation, and termination make innovation measurable rather than narrative — a tactic either clears the bar set at T-12 or it does not.
5. Cross-functional accountability invariants. Clear ownership nine to twelve months before first-patient-in is non-negotiable — the same window this sponsor uses. Innovation collapses when accountability is distributed but responsibility is unclear: everyone owns it, so no one does.
Three Tools. Use Them Monday.
The framework is only useful if it is operational. Three instruments make it so.
Tool 1 — PPI-5 Checklist (Apply at T-12)
Five yes/no questions. Apply before protocol finalization. Every “no” is a structural risk.
☐ Semantic invariants locked? Are cross-study definitions for primary endpoints and response criteria frozen?
☐ Workflow boundaries defined? Are dose-modification and discontinuation boundaries standardized across this therapeutic area?
☐ Site interaction model stable? Is there a single identity layer and consistent support pathway across trials?
☐ Evidence thresholds set? Are adoption, continuation, and termination criteria pre-specified for every active tactic?
☐ Accountability confirmed? Is cross-functional ownership named, with accountable individuals identified?
Scoring: 5/5 = structurally ready. 3–4/5 = scale risk, address before T-9. Below 3/5 = pilot will not survive operational reality.
Tool 2 — Pilot Survivability Score (20-point scale)
Rate each candidate tactic on four dimensions before committing resources.
▸ Semantic readiness (0–5) 0 = definitions vary by trial | 5 = locked cross-portfolio
▸ Workflow stability (0–5) 0 = bespoke per study | 5 = standardized by TA
▸ Site predictability (0–5) 0 = new model every trial | 5 = same interaction layer
▸ Evidence threshold (0–5) 0 = success defined after results | 5 = pre-specified at T-12
Decision rule: PSS ≥ 16 = high survivability. PSS 10–15 = moderate risk, address gaps. PSS < 10 = kill signal, not a coaching opportunity.
Tool 3 — UIW-12 Governance Timeline
The Upstream Innovation Window runs twelve months before first-patient-in. Miss T-12 and you do not recover.
T-12 Apply PPI-5 checklist — Invariant readiness report
T-9 Score tactics on PSS — Kill or proceed decisions
T-6 Harmonize site-facing workflows — Site Predictability Matrix
T-3 Lock invariants, finalize thresholds — Frozen PPI-5 + evidence plan
T-0 Validate adherence at study startup — Invariant Adherence Audit
Executive Guidance
If you do one thing: lock semantic invariants before protocol design.
If you fix one bottleneck: harmonize site-facing workflows.
If you measure one metric: measure evidence-threshold adherence, not adoption rates.
If your invariants aren’t locked by T-12, your pilot is already dead.
The sponsors who pull ahead will be the ones that fix the substrate first — that lock their invariants while everyone else is still launching pilots. This sponsor built the governance layer and proved its limits in public; the next advantage belongs to whoever builds the foundation beneath it. Everyone else will keep running the same experiment and posting the same seventy-nine percent — one pilot at a time.
About the Author
Yogesh Kumar Gupta is a clinical data/standards management professional with 17 years of experience across oncology, cardiovascular, neuroscience, and metabolic disease therapeutic areas in the pharmaceutical industry. His work focuses on data governance, semantic consistency, and clinical trial operational frameworks. The views expressed are solely the author’s own and do not represent those of any employer or organisation.
References
- Alsumidaie, M. “Leading Sponsor Restructures Clinical Ops to Scale Trial Innovation Beyond Pilots.” Clinical Trial Vanguard, April 2026.
- Alsumidaie, M. “Tufts CSDD: New Insights on the Clinical Trial Industry.” Clinical Trial Vanguard, March 2024.
- Galen Growth. “Digital Health Funding in Clinical Trials: Why Execution, Not Discovery, Is Pharma’s Next Existential Bottleneck.”
- HIT Consultant. “The ‘Pilot Purgatory’: Why 80% of Life-Sciences AI Projects Fail.”
- Medhealth Outlook. “Is the Burden of Clinical Trial Technology Sabotaging Sites?”
- CDISC. “Study Data Tabulation Model (SDTM).”
- “Quantifying Site Burden to Optimize Protocol Performance.” Peer-reviewed; via PubMed.
Yogesh Kumar Gupta is an independent researcher in clinical data standards, digital health informatics, and AI safety. His work addresses interpretability and governance across oncology, cardiovascular medicine, and regulatory science. He has presented at OHDSI Europe 2026 and contributes to CDISC working groups including Digital Health Technologies and SDTM Development Specification.
